Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors
Graphical abstract
A series of crown ether fused anilinoquinazolines have been synthesized and evaluated for EGFR inhibition. Compound 12k (Icotinib) showed excellent enzymatic and cellular activities against EGFR. Icotinib is in phase III clinical trials currently.
Section snippets
Acknowledgments
The authors thank the State Key New Drug Development Program (contract Grant Nos. 2008ZX09101-011, 2012ZX09101103). The authors also thank BioPredict, Inc. for allowing the use of their software BioCompare, BioDock and BioInterpreter in modeling.
References and notes (16)
- (a)Chen, L.; Ding, Q.; Gillespie, P.; Kim, K.; Lovey, A. J.; McComas, W. M.; Mullin, J. G., Jr.; Perrotta, A. PCT Int....(b)Chu, X.; Ding, Q.; Jiang, N.; Kim, K.; Lovey, A. J.; McComas, W. M.; Mullin, J. G., Jr.; Tilley, J. W. PCT Int....
- (a)Binnun, E.; Johnson, S. G.; Connolly, P. J.; Middleton, S. A.; Moreno-Mazza, S. J.; Lin, R.; Pandey, N. B.; Wetter,...(b)Lin, R.; Johnson S. G.; Connolly, P. J.; Wetter, S. K.; Binnun, E.; Hughes, T. V.; Murray, W. V.; Adams, M.;...
Liebigs Ann. Chem.
(1989)- et al.
Lung Cancer
(2011)et al.J. Clin. Oncol.
(2011) - et al.
Expert Opin. Ther. Patents
(2008)et al.Clin. Biochem.
(2004)Expert Opin. Ther. Targets
(2003)et al.Curr. Top. Med. Chem.
(2002)et al.Nat. Rev. Mol. Cell Biol.
(2001)et al.J. Clin. Oncol.
(2007)et al.Exp. Cell Res.
(2011)et al.Med. Res. Rev.
(2012)et al.Respir Med
(2012)et al.Cancer Lett.
(2012) - et al.
Fundam. Clin. Pharmacol.
(2005)et al.Curr. Opin. Oncol.
(2001)et al.Bioorg. Med. Chem. Lett.
(1911)et al.Expert Opin. Drug Saf.
(2011) - et al.
Biol. Targets Ther.
(2007)Lancet Oncol.
(2012) Pathol. Oncol. Res.
(2008)et al.Drugs
(2007)et al.J. Clin. Oncol.
(2005)et al.Oncologist
(2012)
Cited by (62)
Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations
2023, Computers in Biology and MedicineManufacturable Process of a Novel EGFR Inhibitor (Larotinib) for the Treatment of ESCC
2022, Organic Process Research and Development1,4-Dioxepanes, 1,4-Oxathiepanes, and 1,4-Dithiepanes
2021, Comprehensive Heterocyclic Chemistry IVStructure–activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy
2020, European Journal of Medicinal ChemistryCitation Excerpt :As described in Scheme 2, the intermediates 19a-d were generated by nucleophilic substitution reaction of commercially available 18a-c with 2-fluoro-4-nitrophenol or 4-aminophenol under DIPEA in toluene. Then the intermediates 20a-d were successfully obtained by the reduction of nitro of 19a-d [44–46]. The synthesis of target compounds 10a-r and 22a-f were summarized in Scheme 3.
Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents
2018, Bioorganic and Medicinal Chemistry LettersTargeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors
2018, Drug Discovery TodayCitation Excerpt :However, because of an aniline moiety in their structure and clashes with the MET790 side chain, their T790M activity is lower against primary activating EGFR mutants. As a result, their clinical efficacy in patients with T790M mutated NSCLC is limited because of dose-limiting toxicity associated with the inhibition of WT EGFR [37,38]. These third-generation molecules include osimertinib, rociletinib, EGF816, ASP8273, HM-61713/BI-1482694/olmutinib, PF-06747775, PF-06459988 WZ4002, HS-10296, and avitinib.